These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 32651105)

  • 1. Safety, tolerability and efficacy of repeated intravenous infusions of KHK4083, a fully human anti-OX40 monoclonal antibody, in Japanese patients with moderate to severe atopic dermatitis.
    Nakagawa H; Iizuka H; Nemoto O; Shimabe M; Furukawa Y; Kikuta N; Ootaki K
    J Dermatol Sci; 2020 Aug; 99(2):82-89. PubMed ID: 32651105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I randomized study of KHK4083, an anti-OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasis.
    Papp KA; Gooderham MJ; Girard G; Raman M; Strout V
    J Eur Acad Dermatol Venereol; 2017 Aug; 31(8):1324-1332. PubMed ID: 28556418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase 1 Study of KHK4083: A Single-Blind, Randomized, Placebo-Controlled Single-Ascending-Dose Study in Healthy Adults and an Open-Label Multiple-Dose Study in Patients With Ulcerative Colitis.
    Furihata K; Ishiguro Y; Yoshimura N; Ito H; Katsushima S; Kaneko E; Shimabe M; Mukai M; Watanabe R; Morishige T
    Clin Pharmacol Drug Dev; 2021 Aug; 10(8):870-883. PubMed ID: 33512065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
    Blauvelt A; Guttman-Yassky E; Paller AS; Simpson EL; Cork MJ; Weisman J; Browning J; Soong W; Sun X; Chen Z; Kosloski MP; Kamal MA; Delevry D; Chuang CC; O'Malley JT; Bansal A
    Am J Clin Dermatol; 2022 May; 23(3):365-383. PubMed ID: 35567671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study.
    Guttman-Yassky E; Simpson EL; Reich K; Kabashima K; Igawa K; Suzuki T; Mano H; Matsui T; Esfandiari E; Furue M
    Lancet; 2023 Jan; 401(10372):204-214. PubMed ID: 36509097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study.
    Paller AS; Flohr C; Eichenfield LF; Irvine AD; Weisman J; Soung J; Pinto Correia A; Natalie CR; Rodriguez Capriles C; Pierce E; Reifeis S; Gontijo Lima R; Armengol Tubau C; Laquer V; Weidinger S
    Dermatol Ther (Heidelb); 2023 Jul; 13(7):1517-1534. PubMed ID: 37318750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis.
    Guttman-Yassky E; Pavel AB; Zhou L; Estrada YD; Zhang N; Xu H; Peng X; Wen HC; Govas P; Gudi G; Ca V; Fang H; Salhi Y; Back J; Reddy V; Bissonnette R; Maari C; Grossman F; Wolff G
    J Allergy Clin Immunol; 2019 Aug; 144(2):482-493.e7. PubMed ID: 30738171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Stapokibart in Healthy Volunteers and Adult Subjects with Atopic Dermatitis.
    Zhang L; Zhang W; Xu Y; Dong L; Sun Y; Jia Y; Li Z; Chen B; Hou J; Zhang J
    Adv Ther; 2024 Jul; 41(7):2953-2965. PubMed ID: 38833140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.
    Paller AS; Bansal A; Simpson EL; Boguniewicz M; Blauvelt A; Siegfried EC; Guttman-Yassky E; Hultsch T; Chen Z; Mina-Osorio P; Lu Y; Rossi AB; He X; Kamal M; Graham NMH; Pirozzi G; Ruddy M; Eckert L; Gadkari A
    Am J Clin Dermatol; 2020 Feb; 21(1):119-131. PubMed ID: 31823222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
    Beck LA; Thaçi D; Deleuran M; Blauvelt A; Bissonnette R; de Bruin-Weller M; Hide M; Sher L; Hussain I; Chen Z; Khokhar FA; Beazley B; Ruddy M; Patel N; Graham NMH; Ardeleanu M; Shumel B
    Am J Clin Dermatol; 2020 Aug; 21(4):567-577. PubMed ID: 32557382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial.
    Weidinger S; Bieber T; Cork MJ; Reich A; Wilson R; Quaratino S; Stebegg M; Brennan N; Gilbert S; O'Malley JT; Porter-Brown B
    Br J Dermatol; 2023 Oct; 189(5):531-539. PubMed ID: 37463508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
    Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
    Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus.
    Silverberg JI; Pinter A; Pulka G; Poulin Y; Bouaziz JD; Wollenberg A; Murrell DF; Alexis A; Lindsey L; Ahmad F; Piketty C; Clucas A
    J Allergy Clin Immunol; 2020 Jan; 145(1):173-182. PubMed ID: 31449914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial.
    Guttman-Yassky E; Blauvelt A; Eichenfield LF; Paller AS; Armstrong AW; Drew J; Gopalan R; Simpson EL
    JAMA Dermatol; 2020 Apr; 156(4):411-420. PubMed ID: 32101256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OX40 in the Pathogenesis of Atopic Dermatitis-A New Therapeutic Target.
    Croft M; Esfandiari E; Chong C; Hsu H; Kabashima K; Kricorian G; Warren RB; Wollenberg A; Guttman-Yassky E
    Am J Clin Dermatol; 2024 May; 25(3):447-461. PubMed ID: 38236520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2).
    Thaçi D; L Simpson E; Deleuran M; Kataoka Y; Chen Z; Gadkari A; Eckert L; Akinlade B; Graham NMH; Pirozzi G; Ardeleanu M
    J Dermatol Sci; 2019 May; 94(2):266-275. PubMed ID: 31109652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, Ascending Dose, Phase 2 Study of KHK4083, an Anti-OX40 Monoclonal Antibody, in Moderately Active Ulcerative Colitis.
    Kierkus J; Pesegova M; Klopocka M; Brankovic M; Kasai N; Efuni S; Kong J; Nakajima Y; Jordan C; Matsui T; Feagan BG; Strout V
    Crohns Colitis 360; 2020 Jul; 2(3):otaa049. PubMed ID: 36776497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.
    Thaçi D; Simpson EL; Beck LA; Bieber T; Blauvelt A; Papp K; Soong W; Worm M; Szepietowski JC; Sofen H; Kawashima M; Wu R; Weinstein SP; Graham NM; Pirozzi G; Teper A; Sutherland ER; Mastey V; Stahl N; Yancopoulos GD; Ardeleanu M
    Lancet; 2016 Jan; 387(10013):40-52. PubMed ID: 26454361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study.
    Nemoto O; Furue M; Nakagawa H; Shiramoto M; Hanada R; Matsuki S; Imayama S; Kato M; Hasebe I; Taira K; Yamamoto M; Mihara R; Kabashima K; Ruzicka T; Hanifin J; Kumagai Y
    Br J Dermatol; 2016 Feb; 174(2):296-304. PubMed ID: 26409172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial.
    Guttman-Yassky E; Brunner PM; Neumann AU; Khattri S; Pavel AB; Malik K; Singer GK; Baum D; Gilleaudeau P; Sullivan-Whalen M; Rose S; Jim On S; Li X; Fuentes-Duculan J; Estrada Y; Garcet S; Traidl-Hoffmann C; Krueger JG; Lebwohl MG
    J Am Acad Dermatol; 2018 May; 78(5):872-881.e6. PubMed ID: 29353025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.